Sam Klempner, MD, provides insight on HER2-targeted therapy for patients with upper GI cancer, and the Oncology Brothers recap the entire discussion.
FDA Approves Noninvasive Stool RNA Test for Colorectal Cancer Screening
Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.
Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care
Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.
Pembrolizumab Combo Yields Significant OS in HER2+ Gastric/GEJ Cancer
The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.
Expert Perspectives on 2024 ASCO GI Cancers Symposium Trial Updates
Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.
FOLFIRI Plus ICIs Display Anti-Tumor Activity in Gastric/GEJ Cancer
Using FOLFIRI as a doublet with durvalumab or a triplet with durvalumab and tremelimumab yielded positive safety in gastric/GEJ cancers.
Trastuzumab-strf Gets FDA Approval in Overexpressing Breast and Gastric Cancers
Patients with overexpressing breast and gastric cancers may now receive trastuzumab-strf, which has been approved by the FDA.